Opening Bell



May 19, 2022

Market Outlook

Indian markets are likely to open sharply lower tracking a global sell-off as concerns resurfaced about rising inflation and its impact on world economic growth.

Markets Yesterday

- Domestic markets ended marginally lower on the back of losses across IT stocks, which were partially offset by gains in pharma and FMCG stocks amid mixed global cues and rising crude oil prices
- US markets ended lower tracking losses in technology stocks amid release of macroeconomic and mixed global peers


Key Developments

- HPCL's crude throughput is expected at 4.8 MMT, up 13.2% QoQ in Q4FY22 as throughput was partially impacted in Q3FY22 due to refinery shutdown. Marketing segment volumes are expected to increase 4.8% YoY and 3.5% QoQ. On the marketing margins front, we expect weaker profitability QoQ as the company did not pass on increasing crude oil costs to customers. Core GRMs are expected at \$10/bbl on account of increase in product cracks. PAT is expected at ₹ 1182.6 crore, up 36.1% QoQ
- Ashok Leyland is expected to report a robust performance. Total volumes for the quarter were at 48,719 units, up 43% QoQ with M&HCV: LCV ratio for the quarter was at 66:34 vs. 57:43 in Q3FY22. With 6.0% QoQ rise in ASPs at ₹ 17.2 lakh/unit, net sales at ALL are seen at ₹ 8,387 crore (up 51.5% QoQ). With operating leverage at play & marginal rise in input cost, EBITDA & EBITDA margins for the quarter are seen at ₹ 507 crore, 6% (up 200 bps QoQ). Ensuing PAT is seen at ₹ 203 crore

Nifty Hea	at Map								
Tata Consum	754 2.7%	Shree Cement	22,501 2.1%	HUL	2,291 2.1%	Ultratech	6,234 2.1%	Cipla	957 2.0%
Adani Ports	760 2.0%	Hindalco	436 1.8%	Asian Paints	3,100 1.6%	Divis Lab	4,367 1.5%	Bajaj Auto	3,791 1.3%
Sun Pharma	899 0.8%	ITC	267 0.8%	Britannia	3,394 0.8%	Axis Bank	659 0.7%	Hero Moto	2,539 0.6%
Coal India	186 0.5%	UPL	821 0.5%	Maruti	7,567 0.4%	Grasim Ind	1,487 0.4%	Reliance Ind.	2,538 0.4%
Kotak Bank	1,847 0.4%	SBI Life	1,074 0.3%	M&M	913 0.3%	Nestle	16,344 0.1%	Dr Reddy	3,906 0.0%
ONGC	163 0.0%	HDFC Bank	1,314 0.0%	Indusind Bank	903 -0.1%	TCS	3,449 -0.1%	HDFC Ltd	2,185 -0.3%
ICICI Bank	707 -0.4%	Bajaj Finance	5,815 -0.4%	Eicher	2,696 -0.4%	Titan	2,167 -0.4%	Infosys	1,509 -0.6%
Tata Steel	1,180 -0.7%	HCL Tech	1,074 -0.8%	HDFC Life	550 -0.9%	Wipro	481 -1.1%	NTPC	149 -1.3%
Bharti Airtel	696 -1.5%	Bajaj Finserv	12,762 -1.6%	JSW Steel	631 -1.7%	L&T	1,573 -2.0%	SBI	458 -2.0%
Apollo Hospitals	3,735 -2.0%	Tata Motors	415 -2.1%	TechM	1,172 -2.2%	BPCL	332 -3.1%	Power Grid	228 -4.5%

Today's Highlights

Results: Bosch Ltd, HPCL, V Mart, Dr Reddy, V Guard Industries, Novartis, Endurance Tech, Gland Pharma, Ashok Leyland, Concor



	Close	Previous	Chg (%)	MTD(%)	YTD(%)	P/E (1yrfwd)
Sensex	54,209	54,318	-0.2	-5.0	-6.9	22.0
Nifty	16,240	16,259	-0.1	-5.0	-6.4	21.4

Institutional Activity						
	CY20	CY21	YTD CY22	Yesterday	Last 5 Days	
FII (₹ cr)	64,379	-95,085	-2,08,938	-1,255	-16,627	
DII (₹ cr)	-28,544	95,934	1,65,366	376	15,889	

World Indices – Monthly performance

Nikkei	Germany	U.K.	Kospi	France
26,911	14,008	7,438	2,626	6,353
0.4%	-1.0%	-2.2%	-2.5%	-2.8%
Shanghai	BSE	NSE	Dow Jones	Nasdaq
3,086	54,209	16,240	31,490	11,418
-3.4%	-5.2%	-5.4%	-8.5%	-14.4%

Markets Today (Updated till Yesterday)

Commodities	Close	Previous	Chng (%)	MTD(%)	YTD(%)
Gold (₹/10 gm)	50,225	50,173	0.1	-3.0	4.4
Silver (₹/kg)	61,259	61,156	0.2	-3.6	-2.2
Crude (\$/barrel)	113.1	111.9	1.0	3.4	45.3
Copper (\$/tonne)	9,386	9,256	1.4	-3.9	-3.6
Currency					
USD/INR	77.6	77.6	0.0	-1.5	-4.2
EUR/USD	1.1	1.1	-0.3	-0.2	-7.5
USD/YEN	129.2	128.9	0.2	0.4	-10.9
ADRs					
HDFC Bank	54.4	53.0	2.7	-1.4	-16.3
ICICI Bank	18.5	17.7	4.3	-3.0	-6.7
Tata Motors	27.5	26.1	5.5	-2.4	-14.2
Infosys	19.6	18.9	3.5	-1.3	-22.5
Dr Reddys Labs	51.2	50.7	1.0	-4.6	-21.7
Wipro	6.3	6.0	4.0	-2.5	-35.7


ICICI Securities | Retail Research

Key Data Points			
Key Economic Indicator	Period	Latest	Prior Values
RBI Cash Reserve Ratio	N/A	4.50%	4.00%
RBI Repo Rate	N/A	4.40%	4.00%
RBI Reverse Repo Rate	N/A	3.35%	3.35%
CPI YY	Apr	7.79%	6.95%
Current Account Balance	Q3	-9.9bln \$	-9.6bln \$
Exports - USD	Apr	38.19bln\$	34.5bln\$
FX Reserves, USD Final	May	595.95 bln\$	597.72 bln\$
GDP Quarterly yy	Q3	5.40%	8.40%
GDP Annual	FY21	-7.30%	4.20%
Imports - USD	Apr	58.26 bln \$	59.07 bln \$
Industrial Output yy	Mar	1.9%	1.3%
Manufacturing Output	Mar	0.9%	1.1%
Trade Deficit Govt - USD	Apr	-20.07 bln \$	-18.51 bln \$
WPI Food yy	Apr	8.9%	8.7%
	· · · · · · · · · · · · · · · · · · ·		

Action

Dividend


Dividend



ICICI Direct Research



Sectoral Perfo	mance – Monthly	Returns (%)
----------------	-----------------	-------------



Key News for To	ıday		
Company/l ndustry	News	View	Impact
Pipavav	GPPL's Q4FY22 revenues grew 31% QoQ to ₹ 221 crore, led by 2.2x growth in the bulk segment and 4% growth in container segment. Subsequently, absolute EBITDA grew 49% to ₹129 crore (EBITDA margins expanded 700 bps QoQ to 58.4%, led by higher operating leverage). PAT grew 67% QoQ to ₹ 74 crore. The company reported an exceptional income of ₹ 5.2 crore (related to insurance claim) vs an exceptional income of ₹ 9.9 crore in Q3	to stay disrupted in Q4; minerals, coal and fertiliser saw strong rebound in volumes. Liquid also saw 44% growth in volumes, led by higher LPG volumes. The management commentary regarding any certainty on its "concession agreement" with GMB, remains a key trigger to watch	

34.5%

14.6%

10.7%

Price (₹)

5.00

1.10

38.7%

15.1%

10.9%

Status

Record Date

23-May-22

23-May-22

Apr

Apr

Apr

Ex Date

20-May-22

20-May-22

WPI Fuel yy

WPI Inflation yy

Security name

TRENT

WPI Manuf Inflation yy

KEWAL KIRAN CLOTHING

Corporate Action Tracker

🌮 Opening Be	9H	ICICI Direct Research	
Navneet Education		improved profitability for the company. Demand for stationery exports continues to remain strong and the company expects double digit growth in stationery revenues. Also, domestic stationery, which was a laggard, saw a revival in Q4FY22 with domestic stationery revenues increasing from ₹ 44 crore in Q4FY21 to ₹ 97 crore in Q4FY22. NEL is also expanding its presence in the digital content segment,	
Aditya Birla Fashion Retail	ABFRL reported better than estimated results, especially on the profitability front. Revenue grew 25.3% YoY to ₹ 2282.2 crore (I-direct estimate: ₹ 2181.1 crore). Despite fixed overheads returning to normal levels, company reported healthy EBITDA margins of 16.3% (I-direct estimate: 13%)	The accelerated trajectory was on the back of strong growth in Lifestyle brands (Allen Solly, Van Heusen, Louis Philippe and Peter England) with revenues increasing 34% YoY. Pantaloons division reported	
	For Q4FY22 RMTL reported topline of ₹974 crore (up 40% YoY and 5% QoQ), higher than our estimate of ₹ 913 crore. EBITDA for the quarter was at ₹ 169 crore (up 6% YoY and 29% QoQ), higher than our estimate of ₹ 146 crore. Ensuing PAT for Q4FY22 was at ₹ 112 crore, up 2% YoY and 25% QoQ, higher than our estimate of ₹ 100 crore	Q4FY22. For the quarter, topline, EBITDA and PAT, all came in higher than our estimates. During Q4FY22 there was a healthy improvement in EBITDA margins on a sequential basis. For Q4FY22, RMTL's	

🌮 Opening Be	əli	ICICI Direct Research	
ITC	Revenue witnessed growth of 16% to ₹ 16426 crore (I-direct estimate : ₹17198 crore) on the back of 10% growth in cigarettes, 31.8% growth in paperboard, 29.6% growth in agri & 12.3% growth in FMCG businesses. Hotels business also saw strong recovery with 35.4% growth but still remains lower than pre- Covid revenues. FMCG sales growth of 12.3% was led by strong growth in education & stationary segment due to re-opening of schools & sustainable growth in staples. Operating profit rose 16.8% to ₹ 5224.4 crore (I-direct estimate : ₹5303.3 crore). Net profit grew 11.8% to ₹ 4191 crore (I-direct estimate : ₹ 4148 crore). The company declared a final dividend of ₹ 6.25/share. Along with the interim dividend of ₹ 5.25/share, total dividend was at ₹ 11.5/share, which is 4.3% dividend yield	segment from two years of disruption from Covid. Cigarette volumes have been growing at pre-Covid levels and the company has gained market share in the segment in last one year. Further, despite huge commodity inflation, the company has been able to improve its operating margins in the quarter & FY22. We believe ITC is least impacted by commodity inflation given its raw material consist larger proportion of wheat & other agri commodities, which have seen relative less volatility compared to crude & palm oil derivatives. The company has generated strong ₹ 13000 crore free cash flow in FY22 & dividend payout is close to 90%. With the stable taxation on cigarettes & its strategy of improving FMCG business segment margins is expected to work well, going forward	Cross
JK Lakshmi	JK Lashmi Cement's margin improved sequentially by 618 bps to 18.4%. Sales were up 13.3% YoY, 25.5% QoQ to ₹1497.6 crore on resumption of business post end of transporters strike in Chhattisgarh	with sharp cut in other expenses have led	
Granules India	Revenues grew 29% YoY to ₹ 1030 crore, driven by YoY growth of 78% in PFI to ₹ 257 crore and 28% growth in API to ₹ 248 crore. Formulations grew 14% YoY to ₹ 525 crore. EBITDA margins fell 656 bps YoY to 18.7% due to lower gross margins (down 834 bps YoY) and higher other expenditure. EBITDA de-grew 5% YoY to ₹ 193 crore and adjusted PAT declined 13% YoY to ₹ 111 crore. Delta vis-à-vis EBITDA was mainly due to higher tax expense being partially offset by higher other income, lower interest and tax expense	was mainly on back of higher selling price realisation from Paracetamol and new launches in US. EBITDA margins drop was on account of pricing pressure in US and also increase in cost of KSM's, solvents and increase in logistic cost. Two positive takeaways being - 1) sequential improvement in margins despite adverse business condition arising out of supply	⇔

<i>i</i> Opening	3ell	ICICI Direct Research	
TeamLease services	The company reported EBITDA growth of 8.9% QoQ to ₹ 41 crore while EBITDA margins at the company level improved 20 bps QoQ to 2.3%. EBITDA margins for general staffing/ specialized staffing/other HR services improved by 10 bps, 50 bps, 560 bps QoQ, respectively. For FY22, it reported EBITDA growth of 20%, 21% in general staffing/specialized staffing, respectively, while other HR services reported EBITDA break-even vs losses in FY21. EBITDA margins for FY22 improved 20bps to 2.2%. Revenue is up 33% in FY22 at ₹5838 crore. Productivity ratio has declined 10.6% QoQ to 346	impressive vs last year because of turnaround of other HR services. Going into FY23, the company expects continued robust hiring from IT, Telecom, Pharma, Retail, E-commerce as well as from manufacturing space which is expected drive revenues while continued improvement in Other HR services and specialized staffing will drive the margins. Productivity ratio drop was due to front loaded hiring to cater massive associates addition of 50K in FY22 and also due to	
Endurance Technologi es	Maxwell Energy Systems Private Limited (Maxwell), for acquiring 100% of its equity share capital in a phased manner. Maxwell is in the business of embedded electronics particularly in battery management systems for vehicles including electric vehicles (EV)	Endurance for the acquisition is ₹ 308 crore (₹ 135 crore upfront for 51% stake and ₹ 173 crore spread out over five years linked to certain milestones), which optically looks expensive (~15x P/S on trailing basis) however is to be viewed with the potential that it holds given the thrust on electrification globally. Given the size of acquisition is small and healthy B/S at Endurance, we would rate it as neutral at this point in time and would await management commentary with the results conference call over the bigger plans with the target. Maxwell's website mentions	€

🕖 Opening B	ell ICICI Direct Research	
Sandhar Technologi es	Sandhar Technologies (STL) reported a STL, a leading auto ancillary player, muted performance in Q4FY22 with EBITDA margins falling short of double digit trajectory a key disappointment. Net sales for the quarter came in at ₹ 684 crore, up 12 % YoY. EBITDA in Q4FY22 was at 63 crore, up 20% YoY with corresponding EBITDA margins at 9.2%, up 70 bps QoQ. PAT in Q4FY22 was at 63 crore, up 20% YoY with corresponding EBITDA margins at ₹ 18 crore, up 18% YoY. For full year basis (FY22), the company did sales of ₹ 2,324 crore, up 25% YoY with PAT at ₹ 56 crore, up 25% YoY with PAT at ₹ 56 crore, up 25% YoY with PAT at ₹ 56 crore, up 25% YoY with decline in EBITDA margins to ~9%, down ~100 bps YoY	Ţ
Somany Ceramics	Somany reported a weak performance with tiles volumes decline and sharp margin contraction with higher gas and other input prices. The topline was up 9.4% YoY at ₹ 616.8 crore. Tiles Revenues were up 9.1% YoY at ₹ 535.8 crore with volumes down 4.5% YoY and realisations up 14% YoY, given the price hikes taken in last few quarters. EBITDA was at ₹ 50.6 crore, down ~43% YoY owing to higher input and gas prices leading to decline of 605 bps in gross margins at 29.8%. The resultant margins were at 8.2%, down 756 bps YoY. PAT was at ₹ 17.2 crore, down ~43% YoY given the margin pressure	
Lupin	Revenues grew 3% YoY to ₹ 3883 crore, wherein domestic formulations grew 5% YoY to ₹ 1351 crore. US revenues de-grew 5% YoY to ₹ 1416 crore while South Africa business remained flat YoY to ₹ 210 crore and RoW markets expanded 35% YoY to ₹ 470 crore. API de-grew 14% YoY to ₹ 220 crore (I- direct estimate: ₹ 268 crore). EBITDA margins was down 1287 bps YoY at ~5.8% against I- direct estimate of 13.4%. EBITDA de-grew 68% YoY to ₹ 226 crore (I-direct estimate: ₹ 226 crore (I-direct estimate: ₹ 226 crore (I-direct estimate: ₹ 525 crore (I-direct estimate was profit of ₹ 245 crore) vs. adjusted profit of ₹ 460 crore in Q4FY21. Delta vis-à-vis EBITDA was mainly due to higher interest, depreciation and tax expense along with lower other income in this quarter. The board of directors recommended a dividend of ₹ 4 per equity share	Ţ

🌈 Opening B	ieli		ICICI Direct Research	
Pidilite	Pidilite's consolidated revenue increased ~12% YoY to ~₹ 2507 crore led by price hikes. However, volume growth was low due to supply chain disruptions and higher base of Q4FY21. Higher raw material prices dragged down gross margin by 730 bps YoY and EBITDA fell 461 bps YoY to 16%. Lower EBITDA margin and decline in other income brought down PAT by ~17% YoY to ~₹ 254 crore	performance on Gross margin rer despite price hike EBITDA margin. supply chain disru higher base of company's volum await managemer	the profitability front. mained under pressure es leading to decline in Additionally, Covid-led uptions and significantly Q4FY21 affected the e offtake. However, we	Ţ
-	Revenue increased 55.2%YoY to ₹ 2405.9 crore in Q4FY22. Sales volume was 7.7 mmscmd, up 13.5% YoY. Gross margins fell ₹ 0.9/scm YoY to ₹ 12.6/scm as higher realisation was offset by higher gas costs. EBITDA was at ₹ 500.5 crore, up 1.8% YoY leading to PAT of ₹ 361.6 crore, up 9.2% YoY	profitability front. lower than estimat in line with expe- prices in Q4FY22 gas costs. In the cu TD), the company post increase in A	While sales volume was ted, gross margins were ctations. IGL had hiked to pass on increase in urrent quarter (Q1FY23E- has further hiked prices APM gas costs. Volume vith steady margins will	\Rightarrow

Key developments (Continued...)

A A C D H

- Dr Reddy's revenues are likely to grow ~6% YoY to ₹ 5062.5 crore, mainly due to ~11% growth in domestic formulations to ₹ 937.4 crore and 12% YoY growth in US business to ₹ 1951.2 crore. Russia & CIS revenues are likely to de-grow by 10% YoY to ₹ 534 crore while RoW markets are expected to grow by 25% to ₹ 364 crore. Europe and PSAI business are likely to remain muted YoY at ₹ 388 and ₹ 791 crore respectively. EBITDA margins are likely to decrease by 165 bps YoY to 20.4%. EBITDA is expected to be flat YoY at ₹ 1034.6 crore. Adjusted PAT is likely to remain flat YoY to ₹ 562 crore. [Note: Profitability may be impacted significantly due to possible Russia-CIS inventory adjustments]
- V-Guard is likely to report sales growth of ~5% YoY to ₹ 898 crore largely driven by price hikes. The electrical segment revenue is likely to increase 11% YoY to ₹ 432 crore led by ~20% price hike in the wire segment. The EBITDA margin is likely to decline 351 bps YoY to 9.4% mainly due to higher raw material cost and low operating leverage. As a result, PAT may see a decline of 23% YoY to ~₹ 53 crore in Q4FY22
- LICHF reported decent set of numbers. NII grew 9% YoY to ₹ 1,637 crore in Q4FY22. Net interest margin was flat at 2.65% YoY. Provisions declined significantly as a result PAT jumped by 180% YoY at ₹ 1118 crore. The total outstanding portfolio increased by 8% YoY to ₹ 2,51,120 crore out of which, the Individual Home Loan portfolio grew 13% YoY at ₹ 2,04230 crore and Project loan portfolio shrunk to ₹ 12,978 crore as on March 31, 2022. Stage 3 assets improved to 4.64% vs 5.04% in Q3FY22
- TVS Motor has launched the new TVS iQube Electric Scooter with a host of exciting new age connected features as well as fast charging capabilities. It is being launches with three variants i.e. TVS iQube, TVS iQube S (both with on-road range of 100 Km, powered by 3.4 Kwhr battery) and TVS iQube ST (on-road range of 140 Km, powered by 5.1 Kwhr battery). Company has started bookings for the TVS iQube and TVS iQube S variants with pricing fixed at ₹1-1.1 lakh/unit (on-road Delhi including FAME and state subsidy). While it has not disclosed pricing for TVS iQube ST, however has started accepting pre-bookings for the same.
- Birlasoft informed the stock exchanges that in its proposed meeting on May 23, 2022 for Q4 results, board of directors will also consider buyback of shares
- Aurobindo's unit-V facility has received EIR from USFDA based on the inspection review and written responses provided by the company for five Form 483 observations. Unit-V is an API manufacturing unit for antibiotics (sterile and non sterile) and underwent a pre-approval inspection from February 8-15, 202.
- Sun Pharma plans to launch a first-in-class oral drug, Bempedoic Acid, in India for reducing low-density lipoprotein (LDL) cholesterol under the brand name, Brillo. It is indicated for people who have an inherited genetic disorder that causes high cholesterol levels. As per IMS MAT Jan 2022 data, the size of the statin market in India is ~ 4,300 crore


f Opening Bell

- Ruchi Soya Industries has agreed to acquire the food retail business of Patanjali Ayurved on a slump sale basis, for a total consideration of ₹ 690 crore. The former will change its name to "Patanjali Foods Ltd." The transaction is expected to expand the company's existing product portfolio and strengthen its market position. Patanjali Ayurved reported revenues of approximately ₹ 10,605 crore for the last fiscal year
- According to Financial Express, Walmart Inc.'s Indian payments unit PhonePe will acquire two wealth management firms for a total enterprise value of \$75 million bringing the retail giant head-to-head with Amazon.com Inc. in the country's rapidly-expanding money management segment. PhonePe will buy WealthDesk for about \$50 million and OpenQ for nearly \$25 million. The acquisitions will help PhonePe widen its offerings in a lucrative payments market where tech giants including Google, Amazon and SoftBank Group Corp backed Paytm compete
- As per Times of India, the sharp surge in inflation in India will require front-loading of interest rate increases, two members of the central bank's Monetary Policy Committee (MPC) said in minutes of its May 4 meeting
- According to The Economic Times, credit rating agencies have sought the intervention of their primary regulator, SEBI, in the wake of new directions from the Reserve Bank of India (RBI) and the contradictions that have surfaced in the views of the two financial market watchdogs. The central bank has said ratings given on loans to a company cannot be notched up on the basis of diluted and non-prudent support structures such as letter of comfort, letter of support or undertaking, and other covers like pledge of shares
- As per The Economic Times, IDBI Bank has divested its entire stake of over 19% (holding of 6,23,23,800 fully paid-up equity shares) in ARCIL to Avenue India Resurgence Pte. The lender, however, did not disclose the deal value. With this, the bank ceases to be a sponsor shareholder of ARCIL
- According to Mint, the central government will come up with a fresh disinvestment plan for BPCL after the company's expansion initiatives are completed
- The government has approved amendments to the National Policy on Biofuels and advanced the target of blending 20% ethanol-blended petrol by five years from 2030 to 2025-26



Pivot Points						
Index/Stocks	Trend	Close	S1	S2	R1	R2
S&P BSE SENSEX INDEX	Positive	54208.5	53964	53720	54619	55030
NIFTY 50	Positive	16240.3	16168	16095	16357	16473
AARTI INDUS LTD	Positive	785.5	773	761	794	804
ASIAN PAINTS LTD	Positive	3100.1	3041	2982	3144	3188
DIVI LABS LTD	Positive	4366.7	4298	4230	4410	4454
STATE BANK IND	Neutral	458.0	453	450	465	473
DR REDDY'S LABS	Positive	3905.8	3863	3821	3966	4027
TATA MOTORS LTD	Positive	415.2	411	406	424	432
INDUSIND BANK	Positive	903.2	896	888	915	926
BATA INDIA LTD	Positive	1754.5	1741	1727	1774	1793
TATA CONSULTANCY	Positive	3448.8	3429	3410	3481	3514
GRANULES INDIA	Positive	263.1	255	246	269	274
BHARAT PETROL	Neutral	331.9	327	321	343	353
INDIAN RAILWAY C	Positive	671.8	663	654	687	702
RELIANCE INDS	Positive	2538.4	2508	2477	2570	2601
AU SMALL FINANCE	Neutral	1283.1	1263	1243	1320	1357
CESC LTD	Positive	79.7	78	78	81	83

Nifty Call – Put Strike (Number of shares in lakh) – May, 2022



Technical Outlook

Equity benchmarks took a breather after Tuesday's sharp up move. The Nifty lost 19 points to conclude Wednesday's session at 16240. In the coming session, index is likely to witness gap down opening tracking weak global cues. we expect index to trade with corrective bias amid elevated volatility owing to weekly derivative expiry. Hence, use intraday pullback towards 16055-16080 for creating short position for the target of 15957 In the coming session index is likely to witness gap down opening tracking weak global cues. Going ahead, strong support for the Nifty is placed at 15600. We believe, for a sustainable pullback to materialize index need to form a higher base from here on, else extension of corrective bias towards 15600 tracking volatile global cues. In the process, 16400 will be the key level to watch on the upside as it is the 38.2% retracement of past four weeks decline (17414-15735)

CNX Nifty Technic	Intraday	Short term
Trend	Down	Range Bound
Support	15870-15740	15600
Resistance	16050-16130	16400
20 day EMA		16658
200 day EMA		16820

Advances/Declines										
	Advances	Declines	Unchanged							
BSE	1910	1440	116							
NSE	1151	920	65							

Daily Technical Calls
Daily Technical Calls
1. Buy Cipla in the range 944.00-947.00
2. Sell DLF in the range of 322.00-324.00
3. Buy Persistent in the range of 3840-3910
All recommendations of May Future
See Momentum Pick for more details
Intraday Derivative Strategy
i) Ita Limitad (CMP: 261.7)

I) ITC LIMITED (UN	1P: 261./)	
Buy ITC May Fut at	₹ 261.2-262.2	
Target 1: 264.5	Target 2: 268.7	
Stop Loss: 258.9		

ii) Rbl Bank (CMP: 119.85)

Target 1: 116.7	Target 2: 112.1	
Stop Loss: 123		

See Derivatives view for more details

🌈 Open	ing Bell								ICICI Dire	ct Resear	ch
Results/E	Events Calendar			,		1				1	
02	May Monday	03	May Tuesday	04	May Wednesday	05	May Thursday	06	May Friday	07	May Saturday
Mahindra Holidays Ramkrishna Forging, Solar Ind HDFC Itd, Alembic Pharma Tata Steel MGM Fin, Inox Leisure Hero Moto. Castrol, Astec life, Saregama Titan, Kec Int		Tata consumer,ABB,EIH Dabur,Marico,Firstsource Gr Havells India PGHL,Intellect design arena CS			Grindwell No CSB Bank,Fe Reliance Ind	rton,Vesuvius In,ENIL Ideral Bank	Navin Fluorine Siyaram Silk Mangalam Cement DCB Bank				
09	May Monday	10	May Tuesday	11	May Wednesday	12	May Thursday	13	May Friday	14	May Saturday
BASF India,P SRF VST Tillers Tr Mold Trek Pa		Asian Paints, Cipla,Awadh	ac,Polycab,Taj GVK Hote Ajanta Pharma,EPL Sugar,Vodafone Idea Alahanagar Gas				olin Point, Apollo Tyres e Enterprise on, Coforge	1	er Motors,BKT BOB,Bandhan Bank nts	Vinati Organic Neogen chem Avenue Super Triveni Eng & Affle India	iicals rmarts
16	May Monday	17	May Tuesday	18	May Wednesday	19	May Thursday	20	May Friday	21	May Saturday
Bharat Forge MCX Greenply Century Ply Shankara	,VIP Industries	1	Anup Engg	Pidilite Indutries,Navneet,LIC housing Dr Reddy Granuels India,Indraprastha Gas Novartis,		Dr Reddy,V Guard Ind. Novartis,Endurance Tech Gland Pharma		Amara Raja Bat,Pfizer.IDFC Ltd Hester Biosciences, Cochin Shipyard Indigo Paints, JK Tyre, Sobha, NTPC Ador Welding, Advanced Enzyme Thermax, Zydus Lifescience, Narayana		BHEL Powergrid	
23 Pricol,HG Infr Bharat Elect. Divis Action Constr Graphite India		24 May Tuesday JM Financial,Gabriel,Minda Ind MBL,Dalmia Bharat Sugar,Indo Cour Adani Ports,Jyothi Labs,Eclerx ZF Commercial Vehicle,Phoneix Mills IPCA,Aster DM,Balrampur chini		Coal India,Shalby		26 May Thursday Page Industries,NMDC Hindalco,Healthcare Global Motherson Sumi,Hawking Cooker Berger Paints,sudarshan chem Colgate Palmolive		27 May Friday Ramco Cements, Engineers India ESAB, Sumitomo Chem, Mah Seamles Nirlon, Timken India, Atul Auto TCI Express, Glenmark Pharma JSW Steel, Astral, Info Edge		28 May Saturday M&M stTK Prestige Time Technoplast	
30 Sun Pharma KNR Constru	May Monday ^{ction}	31	May Tuesday	01	June Wednesday	02	June Thursday	03	June Friday	04	June Saturday

Major E	Economic Events this We	ek				Result Preview									
Date	Event	Country	Period	Actual	Expected	/ Company	Revenue	Ch	g(%)	EBITDA	Chg	(%)	PAT	Chg	J(%)
17-May	WPI Food	IN	May	8.35%	-	₹ Crore	Q4FY22E	YoY	QoQ	Q4FY22E	YoY	QoQ	Q4FY22E	YoY	QoQ
17-May	WPI Fuel	IN	May	38.66%	-	HPCL	1,31,206.2	54.0	26.9	2,257.9	-51.6	20.7	1,182.6	-60.8	36.1
17-May	WPI Inflation	IN	May	15.08%	14.48%	V Mart	483.9	37.5	-22.6	19.9	-41.0	-85.0	-37.6	NA	NA
17-May	WPI Manufacturing Inflation	IN	May	10.85%	-	Dr Reddy	5,062.5	6.2	-5.2	1,034.6	-1.8	-14.9	562.0	0.8	-19.2
17-May	Retail Sales MoM	US	May	0.90%	0.90%	V Guard	898.4	5.1	-7.1	84.5	-23.5	-2.7	53.0	-22.6	-1.8
17-May	Industrial Production YoY	US	May	6.40%	-	Ashok Leyland	8,387.0	19.8	51.5	507.0	-5.1	126.4	203.0	-15.9	NM
17-May	GDP YoY	JP	May	-1.00%	-1.80%										
18-May	Industrial Production MoM	JP	May	0.30%	0.30%										
18-May	CPI	UK	May	9.00%	9.10%										
18-May	Core CPI	EU	May	7.40%	7.50%										
18-May	Trade Balance	JP	May	-839.2B	1,150B										
18-May	Crude Oil Inventories	US	May	-3.394M	1.383M										
Date	Event	Country	Period	Expected	Previous										
19-May	Initial Jobless Claims	US	May	200k	203k	Recent Releases									
19-May	National Core CPI	JP	May	2.10%	0.80%	necent neleases									
20-May	Bank Loan Growth	IN	May	-	11.10%	Date	Repor	t							
20-May	Deposit Growth	IN	May	-	9.80%	May 17, 2022	Result	Upda	ate- B	ajaj Electri	cals				
20-May	FX Reserves, USD	IN	May	-	595.95B	May 17, 2022	Result	Upda	ate- VI	P Industri	es				
						May 17, 2022	Result	Upda	ate- Co	entury Ply	wood				
						May 17, 2022	Result	Upda	ate- Ka	ajaria Cera	mics				

May 17, 2022

Result Update- Indoco Remedies



Pankaj Pandey

Head – Research pankaj.pandey@icicisecurities.com

ICICI Direct Research Desk, ICICI Securities Limited, 1st Floor, Akruti Trade Centre, Road No 7, MIDC Andheri (East) Mumbai – 400 093 research@icicidirect.com

Disclaimer

ANALYST CERTIFICATION

I/We, Pankaj Pandey, Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products.

ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH00000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or actual/ beneficial ownership of one percent or more or other material conflict of interest various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.